Dr. Nicole Onetto joined NBE-Therapeutics’ Board of Directors in November 2017 as an independent Board member. Dr. Onetto is an independent consultant in oncology, drug development and translational research. She was previously Deputy Director & Chief Scientific Officer at the Ontario Institute for Cancer Research. Prior to this she was Chief Medical Officer at ZymoGenetics Inc, and Chief Medical Officer at OSI Pharmaceuticals, Inc. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, and Gilead Sciences, Inc.

Dr. Onetto is a member of the Board for both Basilea Pharmaceutica AG and Sunesis Pharmaceuticals, Inc. and was previously a board member for Sierra Oncology, Inc. and for ImmunoGen Inc.

She holds a Doctorate in Medicine from the University of Paris, is Board certified from the University of Paris in pediatrics and hematology and holds a Master of Pharmacology from the University of Montréal.